“…In support, Malik's group demonstrated that TRPM2-mediated Ca 2+ influx is required for VE-cadherin phosphorylation at Y73, a process necessary for the disassembly of adherens junctions and opening of the paracellular pathways, thereby allowing PMN adhesion and transmigration (Mittal et al, 2017). Indeed, when challenged with LPS injection, TRPM2-depleted mice exhibited reduced PMN accumulation, inflammation, and mortality, suggesting a protective role of TRPM2 inhibition (Mittal et al, 2017). Using the 8-Br-cADPR TRPM2 antagonist, Eraslan and colleagues also showed the therapeutic benefits of TRPM2 inhibition, as it prevented ischemic acute kidney inflammation through reduced production of TNF-α, IL-1β, and myeloperoxidase activity (Eraslan et al, 2019).…”